JAGUAR HEALTH INC (JAGX)
US47010C8055 - Common Stock
We assign a fundamental rating of 2 out of 10 to JAGX. JAGX was compared to 193 industry peers in the Pharmaceuticals industry. JAGX has a bad profitability rating. Also its financial health evaluation is rather negative. JAGX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
JAGX had negative earnings in the past year.
In the past year JAGX has reported a negative cash flow from operations.
JAGX had negative earnings in each of the past 5 years.
JAGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -64.55%, JAGX is doing worse than 68.59% of the companies in the same industry.
JAGX has a worse Return On Equity (-234.48%) than 72.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.55% | ||
| ROE | -234.48% | ||
| ROIC | N/A |
ROA(3y)-93.37%
ROA(5y)-98.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
JAGX has a Gross Margin of 80.11%. This is amongst the best in the industry. JAGX outperforms 85.34% of its industry peers.
In the last couple of years the Gross Margin of JAGX has grown nicely.
The Profit Margin and Operating Margin are not available for JAGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.75%
GM growth 5Y16.19%
2. Health
2.1 Basic Checks
JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
JAGX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for JAGX has been reduced compared to 5 years ago.
Compared to 1 year ago, JAGX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -9.06, we must say that JAGX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of JAGX (-9.06) is worse than 72.25% of its industry peers.
JAGX has a Debt/Equity ratio of 1.35. This is a high value indicating a heavy dependency on external financing.
JAGX's Debt to Equity ratio of 1.35 is on the low side compared to the rest of the industry. JAGX is outperformed by 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.35 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.06 |
ROIC/WACCN/A
WACC3.93%
2.3 Liquidity
A Current Ratio of 1.84 indicates that JAGX should not have too much problems paying its short term obligations.
JAGX's Current ratio of 1.84 is on the low side compared to the rest of the industry. JAGX is outperformed by 61.26% of its industry peers.
JAGX has a Quick Ratio of 1.36. This is a normal value and indicates that JAGX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.36, JAGX is doing worse than 70.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.84 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
JAGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.45%, which is quite impressive.
JAGX shows a decrease in Revenue. In the last year, the revenue decreased by -2.25%.
The Revenue has been growing by 17.19% on average over the past years. This is quite good.
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.82%
Revenue 1Y (TTM)-2.25%
Revenue growth 3Y1.32%
Revenue growth 5Y17.19%
Sales Q2Q%10.49%
3.2 Future
The Earnings Per Share is expected to grow by 19.18% on average over the next years. This is quite good.
Based on estimates for the next years, JAGX will show a very strong growth in Revenue. The Revenue will grow by 110.13% on average per year.
EPS Next Y86.62%
EPS Next 2Y24.59%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year35.88%
Revenue Next 2Y39.7%
Revenue Next 3Y41.16%
Revenue Next 5Y110.13%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for JAGX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
JAGX's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.59%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
JAGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JAGUAR HEALTH INC
NASDAQ:JAGX (12/18/2024, 4:24:26 PM)
After market: 0.8743 +0.01 (+1.66%)0.86
-0.08 (-8.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.15M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.55% | ||
| ROE | -234.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 80.11% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.35 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.84 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)95.45%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y86.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.25%
Revenue growth 3Y1.32%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y